← All trials
NCT03018041
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2017
- Primary completion
- Feb 1, 2021
- Completion date
- Oct 1, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 174
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Oslo Metropolitan UniversityLead sponsor
- Oslo Metropolitan UniversityOverall official - principal investigator
- Oslo Metropolitan UniversitySponsor investigator
- Drammen sykehusOverall official - principal investigator
- Elverum HospitalOverall official - principal investigator
- Oslo Metropolitan UniversityStudy chair
- Pronova BioPharmaCollaborator
- Drammen sykehusCollaborator
- Elverum HospitalCollaborator
- South-Eastern Norway Regional Health AuthorityCollaborator
- Aalborg UniversityCollaborator
- University of OsloStudy chair
- University of OsloCollaborator
- University of OsloOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.